Advantage Alpha Capital Partners LP Purchases New Shares in SIGA Technologies, Inc. (NASDAQ:SIGA)

Advantage Alpha Capital Partners LP acquired a new position in SIGA Technologies, Inc. (NASDAQ:SIGA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 40,841 shares of the company’s stock, valued at approximately $276,000. Advantage Alpha Capital Partners LP owned approximately 0.06% of SIGA Technologies as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Larson Financial Group LLC bought a new position in shares of SIGA Technologies during the third quarter worth approximately $30,000. DekaBank Deutsche Girozentrale bought a new position in SIGA Technologies during the 2nd quarter worth $40,000. Bayesian Capital Management LP acquired a new position in SIGA Technologies in the 1st quarter valued at $97,000. Lazard Asset Management LLC bought a new stake in shares of SIGA Technologies during the 1st quarter valued at $105,000. Finally, AQR Capital Management LLC acquired a new stake in shares of SIGA Technologies during the 2nd quarter worth $99,000. Institutional investors own 55.40% of the company’s stock.

SIGA Technologies Stock Down 3.8 %

SIGA stock opened at $7.03 on Wednesday. SIGA Technologies, Inc. has a 52 week low of $4.26 and a 52 week high of $12.83. The business has a 50-day simple moving average of $7.00 and a 200 day simple moving average of $7.85. The company has a market cap of $501.94 million, a PE ratio of 5.86 and a beta of 0.89.

SIGA Technologies (NASDAQ:SIGA) last issued its earnings results on Thursday, November 7th. The company reported $0.02 EPS for the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%. The company had revenue of $10.01 million during the quarter. On average, analysts anticipate that SIGA Technologies, Inc. will post 1.04 EPS for the current fiscal year.

About SIGA Technologies

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.